TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Medical Management
Description: Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
Study: NCT01111591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cox2 inhibitor (Celecoxib)
Description: From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cox2 inhibitor (Celecoxib)
Description: From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
Study: NCT02337361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic SBI
Description: Bilingual (English and Spanish) e-SBI with four key components:~1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies.
Study: NCT04294160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: Capsule for oral use
Study: NCT00570739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin HCl and Colesevelam Placebo
Description: One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl tablets and Colesevelam tablets
Description: One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colesevelam placebo
Description: Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
Study: NCT02814214

Intervention type: DEVICE
Intervention: ECG+IEGM
Description: Cardiac Resynchronization Therapy programming adjustments
Study: NCT05129839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lightened and musical baby mobile
Description: Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
Study: NCT03268174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AO+Mist
Description: Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.
Study: NCT00599430

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert excipient

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus acidophilus NCFM
Description: 1e10 CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Lactobacillus acidophilus and Bifidobacterium lactis
Description: 1x10e10 CFU/day
Study: NCT05821504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
Study: NCT04522752

Intervention type: OTHER
Intervention: Size and pathological type of benign epithelial gastric polyp
Description: All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
Study: NCT03078985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation for typical atrial flutter
Description: Typical atrial flutter is treated by catheter ablation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ablation with study device
Description: The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
Study: NCT00394914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleconaril
Description: Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Pleconaril
Description: Placebo nasal suspension
Study: NCT02553915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soybean oil placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soybean oil placebo
Study: NCT02483507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided approach to peripheral vascular access
Description: the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided approach to peripheral vascular access
Description: the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided approach to peripheral vascular access
Description: the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
Study: NCT00634205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate plus doxorubicin
Description: Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
Study: NCT01240850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate+Prednisone
Description: Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT04485208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
Study: NCT02786784

Intervention type: OTHER
Group type: OTHER
Intervention: 6 week exercise treatment
Description: This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
Study: NCT01234961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Redesigning Daily Occupations
Description: The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
Study: NCT03307551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
Study: NCT04294160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Capsule for oral use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Liquid in vial (Concentrate for solution for infusion) for intravenous use
Study: NCT03024242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tight vaginoscope
Study: NCT04279028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted CBT
Description: ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBT
Description: CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
Study: NCT01553786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study: NCT00725010

Intervention type: DRUG
Intervention: Temozolomide
Description: Temozolomide will be administered orally at 75 mg/m\^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m\^2 to 200 mg/m\^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
Study: NCT01290094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3 mg intravenously every 3 months
Study: NCT04294160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Liquid in vial (Concentrate for solution for infusion) for intravenous use
Study: NCT01615991

Intervention type: DRUG
Group type: OTHER
Intervention: Radiosynoviorthesis
Description: Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
Study: NCT02414828

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 3 x 10^8 vp
Description: AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 3 x 10^9 vp
Description: AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 3 x 10^10 vp
Description: AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
Study: NCT03055845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA363
Description: STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA363
Description: STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
Study: NCT01467284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Ahead
Description: Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
Study: NCT03055845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA363
Description: STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
Study: NCT01467284

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Intervention
Description: Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
Study: NCT03055845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
Study: NCT03957915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INA03 administration
Description: INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
Study: NCT03879694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incomplete Freund's Adjuvant
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC
Study: NCT00141687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early ECV between 34 0/7 and 35 6/7 weeks
Description: Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed ECV at or after 37 0/7 weeks
Description: Delayed external cephalic version at or after 37 0/7 weeks of gestation
Study: NCT01170975

Intervention type: DRUG
Group type: OTHER
Intervention: Tesetaxel 10 mg with and then without food
Description: Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state

Intervention type: DRUG
Group type: OTHER
Intervention: Tesetaxel 10 mg without and then with food
Description: Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
Study: NCT03506217

Intervention type: DEVICE
Intervention: Vigileo Flo-trac device
Description: A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
Study: NCT02981784

Intervention type: DRUG
Intervention: Ponatinib (Iclusig®)
Description: Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.

Intervention type: PROCEDURE
Intervention: allogeneic stem cell transplantation
Study: NCT03687359

Intervention type: OTHER
Intervention: Standard of care
Description: Treatment as per standard practice
Study: NCT03717675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross™ Chronic Total Occlusion micro-catheter
Description: The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
Study: NCT02621021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (Cohort 1, Arm 2 and Cohort 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes. (Cohort 1, Arm 1 Retreatment) 4 doses every 3 weeks (+/- 2 days): Pembrolizumab 2mg/kg IV over approximately 30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: young TIL
Description: Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: young TIL
Description: Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.